Intrinsiqs

Is Esperion Therapeutics, Inc. overvalued?

Esperion Therapeutics, Inc. (ESPR) — key valuation metrics and fundamentals.

No verdict
Price
$3.18
Fair value
Current P/E
Normal P/E
Market cap
$661.1M
Dividend yield
99.4%
Return on equity
2.0%
Sector
Healthcare

See the full interactive analysis →

Fair value compares ESPR's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.